FDA Halts The TIDE Of New Avandia Patients; Informed Consent Changes Loom
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency's partial clinical hold prevents new subjects from enrolling in GlaxoSmithKline's postmarketing safety study of rosiglitazone and suggests informed consent process for current subjects be revised to reflect advisory committee deliberations on the drug's safety.
You may also be interested in...
FDA Keeps Avandia On The Market But Looks To RECORD For More Clarity On CV Risk
Rosiglitazone will be available under a Risk Evaluation and Mitigation Strategy with restricted distribution pending an independent panel's re-adjudication of CV endpoints in the much-maligned, open-label RECORD study.
FDA Keeps Avandia On The Market But Looks To RECORD For More Clarity On CV Risk
Rosiglitazone will be available under a Risk Evaluation and Mitigation Strategy with restricted distribution pending an independent panel's re-adjudication of CV endpoints in the much-maligned, open-label RECORD study.
Avandia, Actos Comparative Safety Evaluation "Not Novel," FDA Says
FDA used the Avandia advisory committee to defend its view that marketing withdrawal decisions can be based on safety comparisons to other drugs approved for the same condition